-
1
-
-
27644510382
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
-
Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721-4732.
-
(2005)
Antimicrob Agents Chemother.
, vol.49
, Issue.11
, pp. 4721-4732
-
-
Dorr, P.1
Westby, M.2
Dobbs, S.3
-
3
-
-
84859947440
-
Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
-
O121
-
Vandekerckhove LPR, Wensing AMJ, Kaiser R, et al. O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing. J Int AIDS Soc. 2010; 13(suppl 4):O7.
-
(2010)
J Int AIDS Soc.
, vol.13
, Issue.SUPPL. 4
-
-
Vandekerckhove, L.P.R.1
Wensing, A.M.J.2
Kaiser, R.3
-
4
-
-
84877911362
-
-
Electronic Medicines Compendium Viiv Healthcare UK Limited accessed April 25, 2011
-
Electronic Medicines Compendium. 2011 Summary of Product Characteristics: Celsentri 150 mg film-coated tablets. Viiv Healthcare UK Limited. http://www.medicines.org.uk/emc/medicine/20386. Accessed April 25, 2011.
-
2011 Summary of Product Characteristics: Celsentri 150 Mg Film-coated Tablets
-
-
-
5
-
-
84877915338
-
-
accessed April 25, 2011
-
Food and Drugs Administration. 2011 Full prescribing information: Celsentri. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022128s004lbl.pdf. Accessed April 25, 2011.
-
2011 Full Prescribing Information: Celsentri
-
-
-
6
-
-
80052476919
-
Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping [abstract PE3.4/8]
-
Cologne, Germany
-
McGovern RA, Dong W, Mo T, et al. In: Program and abstracts of the 12th European AIDS Conference. Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict Maraviroc responses in treatment experienced (TE) patients using population V3 genotyping [abstract PE3.4/8]. Cologne, Germany; 2009:11-14.
-
(2009)
Program and Abstracts of the 12th European AIDS Conference
, pp. 11-14
-
-
McGovern, R.A.1
Dong, W.2
Mo, T.3
-
7
-
-
33846932573
-
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: Aids clinical trial group A5211
-
Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44(4): 591-595.
-
(2007)
Clin Infect Dis.
, vol.44
, Issue.4
, pp. 591-595
-
-
Wilkin, T.J.1
Su, Z.2
Kuritzkes, D.R.3
-
8
-
-
54849146700
-
Maraviroc for previously treated patients with R5 HIV-1 infection
-
Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008; 359(14):1429-1441.
-
(2008)
N Engl J Med.
, vol.359
, Issue.14
, pp. 1429-1441
-
-
Gulick, R.M.1
Lalezari, J.2
Goodrich, J.3
-
9
-
-
35048870707
-
Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1
-
Paper presented at Chicago, IL
-
Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of Maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1. Paper presented at 47th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007.
-
(2007)
47th International Conference on Antimicrobial Agents and Chemotherapy
-
-
Lalezari, J.1
Goodrich, J.2
DeJesus, E.3
-
10
-
-
55049103539
-
Efficacy and safety of maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America (MOTIVATE2): 48 week results
-
Paper presented at Madrid, Spain
-
Fatkenheuer G, Konaourina I, Nelson M, et al. Efficacy and safety of Maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America (MOTIVATE2): 48 week results. Paper presented at 11th European AIDS Conference. Madrid, Spain; 2007.
-
(2007)
11th European AIDS Conference
-
-
Fatkenheuer, G.1
Konaourina, I.2
Nelson, M.3
-
12
-
-
77749271329
-
Maraviroc versus efavirenz, both in combination with zidovudine- lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection
-
Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201(6):803-813.
-
(2010)
J Infect Dis.
, vol.201
, Issue.6
, pp. 803-813
-
-
Cooper, D.A.1
Heera, J.2
Goodrich, J.3
|